First evidence of the conversion of paracetamol to AM404 in human cerebrospinal fluid by Sharma, Chhaya et al.
© 2017 Sharma et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms. 
php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work 
you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For 
permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
Journal of Pain Research  2017:10 2703–2709
Journal of Pain Research Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
2703
O R I G I N A L  R E S E A R C H
open access to scientiﬁc and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/JPR.S143500
First evidence of the conversion of paracetamol 
??? ????????????????????????????????
Chhaya V Sharma,1 Jamie H 
Long,2 Seema Shah,1 Junia 
Rahman,1 David Perrett,3 
Samir S Ayoub,4 Vivek 
Mehta1
1Pain & Anaesthesia Research Centre, 
St Bartholomew’s and The Royal 
London Hospitals, Barts Health NHS 
Trust, London, UK; 2Barts & The 
London School of Medicine, Queen 
Mary University of London, London, 
UK; 3BioAnalytical Science, Barts & 
The London School of Medicine, 
Queen Mary University of London, 
London, UK; 4School of Health, Sport 
and Bioscience, Medicines Research 
Group, University of East London, 
London, UK 
Abstract: Paracetamol is arguably the most commonly used analgesic and antipyretic drug 
worldwide, however its mechanism of action is still not fully established. It has been shown to 
exert effects through multiple pathways, some actions suggested to be mediated via N-arachi-
donoylphenolamine (AM404). AM404, formed through conjugation of paracetamol-derived 
p-aminophenol with arachidonic acid in the brain, is an activator of the capsaicin receptor, 
TRPV1, and inhibits the reuptake of the endocannabinoid, anandamide, into postsynaptic  neurons, 
as well as inhibiting synthesis of PGE
2
 by COX-2. However, the presence of AM404 in the cen-
tral nervous system following administration of paracetamol has not yet been demonstrated in 
humans. Cerebrospinal ﬂuid (CSF) and blood were collected from 26 adult male patients between 
10 and 211 minutes following intravenous administration of 1 g of paracetamol. Paracetamol 
was measured by high-performance liquid chromatography with UV detection. AM404 was 
measured by liquid chromatography-tandem mass spectrometry. AM404 was detected in 17 of 
the 26 evaluable CSF samples at 5–40 nmol⋅L–1. Paracetamol was measurable in CSF within 10 
minutes, with a maximum measured concentration of 60 μmol⋅L–1 at 206 minutes. This study is 
the ﬁrst to report on the presence of AM404 in human CSF following paracetamol administra-
tion. This may represent an important ﬁnding in our understanding of paracetamol’s mechanism 
of action, although measured concentrations were far below the previously documented IC50 
for this metabolite. 
Keywords: acetaminophen, paracetamol, paracetamol: mechanism of action, AM404, 
N- arachidonoylphenolamine, pharmacology - theories of analgesic action
Introduction
Despite its discovery over a century ago and ubiquitous clinical use, the mechanism of 
action of paracetamol remains undetermined, although involvement of multiple central 
pathways has been demonstrated. These include effects on prostaglandin production,1,2 
on serotonergic pathways,3,4 and more recently, there has been increasing evidence 
for the roles of the endocannabinoid system and TRPV1 receptor in paracetamol’s 
antinociceptive (though not its hypothermic) effects.5–8
Arachidonoyl ethanolamine (AEA, anandamide) is an endogenous cannabinoid 
present in the human nervous system, with demonstrated antinociceptive actions. 
Its actions are terminated by a two-step inactivation process beginning with its reup-
take from the synaptic cleft into the postsynaptic neuron by a recently characterized 
FAAH-like anandamide transporter (FLAT).9 Inside the neuron, AEA is hydrolyzed 
by the enzyme FAAH. Paracetamol has been suggested to exert its analgesic actions 
by interfering with the reuptake of AEA by using FAAH to form a novel metabolite 
Correspondence: Chhaya V Sharma
Department of Anaesthesia, 4th Floor, 
North Tower, Royal London Hospital, 
Whitechapel, E1 1BB, London, UK
Email Chhaya.Sharma@bartshealth.nhs.uk
Video abstract
Point your SmartPhone at the code above. If you have a  
QR code reader the video abstract will appear. Or use:
http://youtu.be/0umrSpQgoeU
This article was published in the following Dove Press journal:
Journal of Pain Research 
Journal of Pain Research  2017:10submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2704
Sharma et al
N-arachidonoylphenolamine (AM404) through conjugation 
in brain tissue of paracetamol-derived para-aminophenol with 
arachidonic acid.10 The consequence of this is increased AEA 
within the synaptic cleft, producing increased cannabinoid 
receptor (CB
1
) activation.10,11 AM404 is also an activator of 
TRPV1, otherwise known as the capsaicin receptor.7,10
Although the potential central antinociceptive role of 
AM404 has been investigated in animal models, its role 
in humans is not clear. AM404 has been found only as a 
metabolite of paracetamol and is not an endogenous com-
ponent of human or animal nervous systems.7,12 However, its 
presence in cerebrospinal fluid (CSF) following paracetamol 
administration in humans has not been reported. The purpose 
of this pilot study was to investigate whether AM404 is 
present in human CSF following a single intravenous dose 
of paracetamol. 
Methods
Study design and patient randomization
Following approval by the East London Research Ethics 
Committee (ref: 2010-019488-12), EudraCT registration (ref: 
2010-019488-12), and receipt of written informed consent 
from all participants, 30 American Society of Anesthesiology 
classification of perioperative risk of anesthesia I–III adult 
male and female patients, aged between 18 and 80 years, 
were recruited to the study. These patients were scheduled 
to undergo elective urological surgery under spinal anesthe-
sia. Exclusion criteria were any contraindication to spinal 
anesthesia, known hypersensitivity to paracetamol or severe 
hepatocellular insufficiency, patients taking paracetamol 
in the preceding 12 hours, or pregnancy or lactation in 
women. Patients were given a single intravenous dose of 1 
g paracetamol (100 mL solution, Perfalgan; Bristol-Myers 
Squibb Pharmaceutical Limited, Middlesex, UK) as an 
infusion over 10 minutes, and were randomized for sample 
collection at 15, 30, or 120 minutes post-infusion, prior to 
their spinal anesthetic (administration to sampling interval). 
At the time of the lumbar puncture but before injection of 
intrathecal local anesthetic agents, CSF (5 mL) and blood 
(10 mL) samples were collected. 
Randomization was achieved using sealed envelopes 
containing the study group allocation (for sampling at 15, 30, 
or 120 minutes post-paracetamol administration). The sealed 
envelope was selected by a member of the research team not 
involved in data collection or analysis.13 As outcomes of the 
study were measured values of paracetamol and its metabo-
lite, AM404, rather than subjective patient experience, clini-
cal bias was not a concern and masking was not carried out. 
Sample collection and storage
CSF and blood sample were collected into EDTA tubes, 
stored on ice, centrifuged at 1,400× g at 4°C for 15 minutes, 
and then frozen at -20°C until analysis.
Materials
Paracetamol reference samples were from Sigma-Aldrich Co. 
(St Louis, MO, USA); AM404 and palmitoylethanolamide-
d4 (PEA-d4) were from Cayman Chemicals (Ann Arbor, 
MI, USA); ammonium acetate, potassium phosphate, and 
EDTA were from VWR (Lutterworth, UK). Analytical grade 
methanol, acetonitrile, H
2
O, and formic acid were from Fisher 
Scientific UK Ltd (Loughborough, UK).
Measurement of paracetamol in CSF and 
plasma
High-performance liquid chromatography (HPLC) analysis 
was performed on a Jasco system. CSF (100 μL) was diluted 
with 100 μL 50 mM ammonium acetate, pH 5.5, containing 
183 mmol.mL–1 3-aminophenol (internal standard). One 
hundred microliters of plasma was precipitated with 300 μL 
acetonitrile containing 183 mmol.mL–1 3-aminophenol. 
Extracted plasma was centrifuged at 13,000× g for 10 min-
utes and 100 μL supernatant was diluted with 100 μL 50 mM 
potassium phosphate, pH 6.5. Extracts were injected (20 μL 
for CSF, 10 μL for plasma) and separated on a Thermo Sci-
entific C18 column (100 × 4.6 mm, 5 μm). For CSF, elution 
was carried out with 50 mM ammonium acetate (pH 5.5) con-
taining 1 mM EDTA and 5% methanol. For plasma, 50 mM 
potassium phosphate (pH 6.5) containing 1 mM EDTA and 
5% methanol was used. The column was eluted at 1 mL.min–1 
using a Jasco PU-980 pump. Detection was at 242 nm using 
a Jasco UV-975 detector. The retention time for paracetamol 
was 7.05 minutes and that of the internal standard was 
3.5 minutes. The HPLC for paracetamol was calibrated to a 
six-point curve of 0–1.65 mmol⋅L–1. The matrix was PBS for 
CSF and paracetamol-free human plasma for plasma samples. 
The limit of detection for paracetamol in CSF and plasma 
were 54 nmol⋅L–1 and 200 nmol⋅L–1, respectively (S/N=3). 
The limits of quantitation for paracetamol in CSF and plasma 
were 180 nmol⋅L–1 and 600 nmol⋅L–1, respectively (S/N=10). 
Measurement of AM404 in CSF and 
plasma
Liquid chromatography-tandem mass spectrometry (LC-
MS/MS) analysis was performed on a Thermo Scientific 
Accela system attached to a TSQ Vantage mass spectrom-
eter. One hundred microliters of CSF was diluted with 
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100 μL H
2
O. One hundred microliters of plasma was pre-
cipitated with 300 μL acetonitrile containing 329 nmol/L 
internal standard PEA-d4. Extracts (10 μL) were injected 
onto a Waters Acquity BEH phenyl column (2.1 × 50 mm, 
1.7 μm), maintained at 50°C, and eluted at 0.5 mL⋅min–1. 
Initially, the eluent was 95% aqueous, 0.1% formic acid, 
5% methanol, increasing linearly over 3 minutes to 95% 
methanol, 5% aqueous, 0.1% formic acid. This was held 
for 2 minutes and then returned to initial conditions to 
re-equilibrate. Positive electrospray ionization was used, 
with an ion spray voltage of 3,500 V and no decluster-
ing voltage applied. AM404 was detected by monitoring 
the 396.3/110.2 m/z transition using a collision energy 
of 9 V. The detection time for AM404 was 4.25 minutes. 
LC-MS/MS for AM404 was calibrated to an eight-point 
curve 0–300 μmol⋅L–1. The limits of detection of AM404 
in CSF and plasma were 0.1 nmol⋅L–1 and 1.6 nmol⋅L–1, 
respectively (S/N=3). The limits of quantitation for AM404 
in CSF and plasma were 0.5 nmol⋅L–1 and 5 nmol⋅L–1, 
respectively (S/N=10). The LC-MS/MS parameters were 
set as follows: collision gas was argon, spray voltage was 
3,500 V, vaporizer temperature was 300°C, sheath gas pres-
sure was 60 psi, capillary temperature was 270°C, collision 
cell pressure was 1.5 mTorr, and no declustering voltage 
was applied. Full details of the analytical methodologies 
are in Long.14
Results
Patient recruitment
Of the 30 patients recruited, only three were female. Addi-
tionally, two of the patients, one male and one female, were 
later found to have taken an additional dose of paracetamol 
in the previous 12 hours, violating exclusion criteria. Data 
from these four patients were therefore excluded from analy-
sis, such that results from 26 male patients were analyzed 
in total (Table 1).
As expected, given the unpredictable nature of the oper-
ating theater lists, it was not possible to collect samples 
precisely at the intended time points. CSF samples were 
 collected over a range of 10–206 minutes and blood over 
Table 1 Characteristics and sampling times for 26 male patients receiving 1 g intravenous paracetamol at various time intervals prior 
to samples taken for determination of paracetamol and AM404 concentrations in blood and CSF
Randomization 
group (minutes)
Paracetamol- 
CSF time 
(minutes)
Paracetamol-
blood time
 (minutes)
CSF/blood
interval 
(minutes)
Age
(years)
Height
(m)
Weight
(kg)
BMI
(kg.m–2)
15 10 15 5 77.8 1.68 57 20.2
15 15 25 10 78.9 1.65 68 22.7
15 15 21 6 72.7 1.73 68 25.0
15 15 17 2 51.9 1.70 95 32.9
15 15 18 3 34.9 1.75 125 40.8
15 16 25 9 75.1 1.81 92 28.1
15 20 27 7 77.9 1.67 85 30.5
15 20 27 7 56.8 1.63 86 32.4
30 25 29 4 78.8 1.69 52 18.1
15 26 28 2 56.8 1.78 74 23.4
30 33 38 5 56.0 1.71 61 20.9
30 35 35 0 64.7 1.59 78 30.9
30 35 40 5 45.1 1.76 83 26.8
30 38 42 4 77.8 1.82 76 22.9
30 40 46 6 78.6 1.80 109 33.6
120 54 57 2 65.1 1.74 93 30.7
120 56 62 6 75.5 1.90 120 33.2
30 68 74 6 68.7 1.82 93 28.1
120 81 85 4 57.7 1.76 88 28.4
120 82 87 5 54.6 1.53 65 27.8
30 82 85 3 64.0 1.72 81 27.4
30 86 73 7 75.5 1.60 57 22.3
120 117 121 4 76.6 1.70 86 29.8
120 128 134 6 67.7 1.70 77 26.6
120 147 150 3 65.8 1.81 104 31.9
120 206 211 5 56.5 1.75 92 30
Mean (±SD) 65 (12) 1.72 (0.1) 83 (19) 27.9 (5)
Abbreviations: AM404, N-arachidonoylphenolamine; BMI, body mass index; CSF, cerebrospinal fluid.
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15–211 minutes. The mean CSF-blood collection interval 
was 4.9 minutes, ranging 0–10 minutes (Table 1).
CSF and plasma sample analyses
Following intravenous administration, paracetamol and 
AM404 were measured in CSF and plasma (Table 2). 
Paracetamol was detectable in CSF at 10 minutes at 
5 μmol⋅L–1, and at a maximal measured concentration of 
99 μmol⋅L–1. In plasma, the paracetamol concentration ranged 
from 92 to 506 μmol⋅L–1 (Table 2, Figure 1).
AM404 was detected in 17 of the 26 evaluable CSF 
samples from 10 minutes post-administration; 14 of 
these were above the level of reliable quantitation of 
5 nmol⋅L–1, ranging mostly from 5.1 to 57.4 nmol⋅L–1 with 
one anomalous measurement of 166.8 nmol⋅L–1. Measured 
AM404 concentrations in CSF did not correlate with time 
of collection (Figure 2). AM404 was detectable in only 
eight of the 26 plasma samples, with three being above 
the limit of quantitation (>5 nmol⋅L–1), ranging from 6.1 
to 65.4 nmol⋅L–1.
Discussion
Evidence for a pharmacological function of paracetamol-
derived AM404 in rodents has been previously docu-
mented;6,7,10 however, there is no evidence of a similar 
metabolic pathway in human tissues. The current study is 
the first to report on the presence of AM404 in human CSF 
and plasma samples following intravenous administration 
of 1 g paracetamol.
AM404, a putatively active metabolite of paracetamol 
and apparent intermediary in several analgesic pathways 
in animal models,7,10,15 was measured in CSF in 14 of 26 
patients at concentrations of 5.1–57.4 nmol⋅L–1 with an outlier 
at 166.8 nmol⋅L–1; it was also detectable in a further three 
human CSF samples below the level of reliable quantitation 
(<5 nmol⋅L–1). AM404 was not detected in plasma in the 
majority of subjects in this study, consistent with findings 
of Högestätt et al,10 who reported on the absence of AM404 
in rat plasma. In the present study, AM404 above 5 nmol⋅L–1 
was, however, found in the plasma of three of the 26 patients 
(range: 6.1–65.4 nmol⋅L–1). This finding warrants further 
Table 2 Paracetamol and AM404 concentrations in plasma and CSF at various time intervals following intravenous administration of 
1 g of paracetamol in 26 male patients
Plasma CSF
Sample time
(minutes)
Paracetamol
(µmol⋅L–1)
AM404
(nmol⋅L–1)
Sample time
(minutes)
Paracetamol
(µmol⋅L–1)
AM404
(nmol⋅L–1)
15 441 0.0 10 5 5.4
17 286 0.0 15 10 166.8
18 256 0.0 15 5 5.1
21 417 6.1 15 11 0.0
25 402 0.0 15 14 0.0
25 271 65.4 16 12 22.6
27 351 0.0 20 78 10.6
27 289 1.7 20 42 0.0
28 319 0.0 25 24 0.0
29 351 0.0 26 39 2.6
35 506 0.0 33 32 18.2
38 341 0.0 35 37 8.0
40 213 0.0 35 35 0.0
42 265 2.0 38 25 33.9
46 216 23.6 40 19 32.9
57 188 0.0 54 27 0.0
62 167 0.5 56 27 16.2
73 410 4.0 68 55 0.0
74 168 0.0 81 47 0.7
85 206 3.3 82 99 57.4
85 191 0.0 82 61 0.5
87 247 0.0 86 92 8.1
121 118 0.0 117 61 5.2
134 150 0.0 128 62 0.0
150 92 0.0 147 44 0.0
211 130 0.0 206 71 10.4
Abbreviations: AM404, N-arachidonoylphenolamine; CSF, cerebrospinal fluid.
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investigation as there would appear to be a mechanism 
through which AM404 leaks out of the brain and into blood, 
but is only functional in some individuals. 
Although this study reports the presence of AM404 
in human CSF, the exact pathway and clinical relevance 
in humans remain unclear, as the evidence to date on 
AM404 comes largely from animal studies. AM404 has 
been demonstrated in in vitro studies to inhibit reuptake of 
anandamide,9,10,15,16 TRPV1 receptor activity,10,11 and PGE
2
 
production via COX-1 and COX-2,10 in the high nanomolar to 
low micromolar concentration range. Ex vivo animal studies 
have detected levels of AM404 in whole brain tissue equat-
ing to the low nanomolar range following systemic admin-
istration of standard analgesic doses of paracetamol in rats 
Figure 1 The concentration of paracetamol in plasma and CSF over time from 26 male patients given a single intravenous dose of 1 g paracetamol. 
Notes: The concentration of paracetamol was measured using HPLC with a detection time of 7.05 minutes. The concentration of paracetamol in plasma steadily declined 
over time with concentrations ranging from 506 to 92 µmol⋅L–1. In CSF, paracetamol was detected as early as 10 minutes with concentrations ranging from 5 to 99 µmol⋅L–1. 
Abbreviations: CSF, cerebrospinal fluid; HPLC, high-performance liquid chromatography.
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Figure 2 Using LC-MS/MS techniques, AM404 was detected in the CSF of 17 out of the 26 male patients treated with a single intravenous dose of 1 g of paracetamol. 
Notes: In 14 patients, the AM404 concentration was above the detection limit for quantitation (5 nmol⋅L–1) with concentrations ranging from 5.1 to 57.4 nmol⋅L–1 over 10 
to 206 minutes. One patient anomalously showed a very high concentration of AM404 (166.8 nmol⋅L–1 after 15 minutes of paracetamol administration).
Abbreviations: AM404, N-arachidonoylphenolamine; CSF, cerebrospinal fluid; LC-MS/MS, liquid chromatography-tandem mass spectrometry.
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(300 mg.kg–1).10 Using the hot plate test of acute nociception, 
it was found that AM404 at a dose of 10 mg.kg–1 potentiated 
the analgesic action of anandamide.16 Additionally, it was 
shown that 1–10 mg.kg–1 attenuated the formalin-induced 
and chronic constriction injury models of acute and chronic 
pain, respectively, in a CB
1
 receptor-dependent manner.17 
In the present study, nanomolar concentrations of AM404 
were measured in human CSF samples taken from low level 
lumbar puncture. As FAAH is mostly expressed in discrete 
areas of brain tissue,10,16 it is hypothesized that AM404 
would be formed predominantly in the brain following 
administration of paracetamol, from where it diffuses into 
CSF. Ex vivo rat studies support this, with the majority of 
AM404 (following paracetamol administration) being found 
in brain tissue, to a lesser extent in the spinal cord (15-fold 
less), and negligible amounts in plasma.10 It is likely, there-
fore, that human CSF concentrations of AM404 (surrogate 
measures of brain concentration) significantly underesti-
mate the concentration in areas of the brain rich in FAAH. 
Levels measured in this study may therefore correspond to 
much greater amounts formed in human brain following 
paracetamol administration. 
Several investigations aimed at elucidating the phar-
macological mechanism of action of paracetamol have 
reported on paracetamol-derived AM404 playing a key 
role in mediating the analgesic action of paracetamol 
in rodents. Mallet et al demonstrated that inhibition of 
brain FAAH activity, thereby preventing the conversion of 
paracetamol into AM404, suppressed the analgesic action 
of paracetamol in animal models of thermal, mechanical, 
and chemical pain.6 The authors also propose that AM404 
mediates these analgesic actions through activation of CB
1
 
receptor and 5-HT descending inhibitory pathway. These 
findings have been extended to also propose involvement 
of TRPV1 as an analgesic target for paracetamol-derived 
metabolites.18 A recent study by Muramatsu et al reported 
on the metabolism of paracetamol to AM404 in rats at 
doses of paracetamol similar to therapeutic doses in 
humans.19 However, the authors report on a conversion rate 
of paracetamol to AM404 of only 0.0013% with claims of 
analgesic significance, which has not been demonstrated. 
Using pharmacological and genetic approaches to abolish 
the expression or function of FAAH to prevent the synthe-
sis of AM404, it was demonstrated that the hypothermic 
action of paracetamol was similar to control mice and that 
the observed paracetamol-induced hypothermia was not 
dependent on cannabinoids or TRPV1.8
Historical as well as somewhat recent investigations on the 
mechanism of action of paracetamol have focused on direct 
or indirect inhibition of the activity of the COX enzymes as 
the target for the analgesic action of paracetamol.1,2,20,21 These 
in vitro and in vivo experiments consistently demonstrated 
reduction of brain and spinal cord prostaglandin synthesis, 
which is likely to be an action either directly of paracetamol 
or through AM404. 
This study does not report on the pharmacokinetic 
modeling of paracetamol, which has been previously well-
documented.22,23 A study by Kumpulainen et al on the CSF 
pharmacokinetics of paracetamol in children, using serial 
sampling following a 15 mg.kg–1 intravenous dose,22 showed 
paracetamol to be rapidly detectable, within 5 minutes, and 
reaching a maximum concentration equivalent to 119 μmol⋅L–1 
at 57 minutes. Another study, by Singla et al, on plasma and 
CSF pharmacokinetics following intravenous paracetamol in 
healthy adults reports a CSF C
max
 of 39 μmol⋅L–1 at 2 hours.23 
These figures corroborate our findings that paracetamol rapidly 
enters the CSF following intravenous administration, detect-
able as early as 10 minutes in the low μmol⋅L–1 range (Figure 1).
Although this study reports the presence of AM404 in 
human CSF, the extent of its clinical relevance remains unclear. 
The IC50 of AM404 for AEA uptake or EC50 for TRPV1 
activation have not been measured in human CSF, though in 
rat neural tissue, the IC50 for AEA uptake has been found to 
be ~5 μmol⋅L–1.9,10 In the present study, concentrations rang-
ing 5.1–57.4 nmol⋅L–1 with an outlier at 166.8 nmol⋅L–1 were 
measured. However, as mentioned previously, it is possible 
that these low concentrations of AM404 in CSF correspond to 
much higher levels in FAAH-rich areas of the brain.
Further to the identification of a potential central antinoci-
ceptive role of AM404 in animal models, its presence in CSF in 
humans following paracetamol administration is a significant 
finding, reported here for the first time. Whilst this represents 
a potentially important step in furthering our understanding 
of paracetamol’s mechanism(s) of action, given the extremely 
low levels of AM404 detected in the CSF, its role in the clinical 
actions of paracetamol requires further investigation. 
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